Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Golimumab for the Treatment of Hidradenitis Suppurativa in Patients with Previous TNF-α Treatment Failure

Journal of Investigative Dermatology(2021)10.1016/j.jid.2021.04.026Source: DataRank Database

Golimumab for the Treatment of Hidradenitis Suppurativa in Patients with Previous TNF-α Treatment Failure is a research paper published in Journal of Investigative Dermatology (2021). On theSindex it has a DataRank of 0. It has been cited 16 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

16 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 2.42)OA: closedTopics (39)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Judy Hamad,Christopher J. Sayed ORCID,Maria Melendez‐Gonzalez ORCID

Live enrichment

PubMed:34097922 OpenAlex:https://openalex.org/W3172647294

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Grant: 1R21AR075996-01A1

NIAMS NIH HHS

Grant: R21 AR075996

National Institutes of Health

FWCI

2.42

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

closedLicense: http://www.elsevier.com/open-access/userlicense/1.0/

publisherhttps://api.elsevier.com/content/article/PII:S0022202X21013166?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0022202X21013166?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jid.2021.04.026

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34097922

Fields of Study

Hidradenitis Suppurativa and TreatmentsColorectal and Anal CarcinomasChemotherapy-related skin toxicityAdalimumabAdultAntibodies, MonoclonalFemaleHidradenitis SuppurativaHumansInflammationMaleMiddle AgedRetrospective StudiesTreatment FailureTreatment OutcomeTumor Necrosis Factor InhibitorsTumor Necrosis Factor-alpha

MeSH Terms

AdalimumabTumor Necrosis Factor InhibitorsAdultAntibodies, MonoclonalFemaleHumansInflammationMaleMiddle AgedRetrospective StudiesTumor Necrosis Factor-alphaTreatment OutcomeTreatment FailureHidradenitis Suppurativa

Keywords

Hidradenitis suppurativaGolimumabMedicineDermatologyAdalimumabTumor necrosis factor alphaInternal medicineDisease

Sustainable Development Goals

SDG 0: Good health and well-being